Form 10Q Curis Inc For: 13 May
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Curis Inc (CRIS)
The Curis share price today is 0.5000, view NASDAQ CRIS stock exchange data. Track the latest Curis share price with real-time updates on CRIS stock performance including market cap, day range, 52-week range and dividend yield. Access CRIS charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.4901
0.5700
52 wk Range
0.4901
3.1300
Trading near 52-week Low
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.49010.5700
52 wk Range
0.49013.1300
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CRIS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
14.0000
Upside
+2,700.00%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock has taken a big hit over the last week
- Form 13G CURIS For: 24 April
- Investing.com
- Curis receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Form 10Q Curis Inc For: 13 May
- Investing.com
- Form DEF 14A Curis Inc For: 28 April
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 14.0000
(+2,700.00% Upside)
Curis Inc Earnings Call Summary for Q1/2026
- Q1 2026 net loss widened to $24.2M vs $10.6M prior year, driven by non-cash warrant liability adjustments from recent financing.
- R&D expenses fell 24.7% to $6.4M reflecting cost discipline; G&A costs rose 27.5% to $5.1M year-over-year.
- Cash runway extended into late 2027 with anticipated capital from warrant exercises; stock rose 1.8% aftermarket to $0.5609.
- Lead candidate emavusertib remains strategic focus; lymphoma enrollment updates expected 2027, CLL data anticipated by end-2026.
- Company faces high capital dependency on warrant exercises and clinical trial risks in competitive oncology market.
Last Updated: 13-05-2026, 02:44 am
Read Full TranscriptEarnings
Latest Release
19-03-2026
EPS / Forecast
1.23 / -0.77
Revenue / Forecast
1.14M / --
Compare CRIS to Peers and Sector
Metrics to compare | CRIS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCRISPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.6x | −4.0x | −0.5x | |
PEG Ratio | −0.04 | −0.22 | 0.00 | |
Price/Book | 3.7x | 1.0x | 2.6x | |
Price / LTM Sales | 2.1x | 9.9x | 3.2x | |
Upside (Analyst Target) | - | 88.9% | 50.6% | |
Fair Value Upside | Unlock | −0.2% | 7.1% | Unlock |
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Curis (CRIS) Share Price Today?
The Curis share price today is 0.5000.
What is the current Curis (CRIS) share price and day range?
As of 14-05-2026, the Curis share price is 0.5000, with a previous close of 0.5000. The share price has ranged from 0.4901 to 0.5700 today, while the 52-week range spans from 0.4901 to 3.1300.
What Is the Curis Market Cap?
As of today, Curis market cap is 19.9900M.
What Is the Curis (CRIS) Share Price Target?
The average 12-month share price target for Curis is 14.0000, with a high estimate of 20 and a low estimate of 5. 4 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +2,700.00% Upside potential.
What Is Curis's Earnings Per Share (TTM)?
The Curis EPS (TTM) is -1.3300.
From a Technical Analysis Perspective, Is CRIS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Curis Trade On?
Curis is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Curis?
The stock symbol for Curis is "CRIS."
How Many Times Has Curis Stock Split?
Curis has split 2 times.
How Many Employees Does Curis Have?
Curis has 22 employees.
What Is the CRIS After Hours Price?
CRIS's last after hours stock price is 0.4850, the stock has changed by -0.0150, or -3.0000%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.